Latest & greatest articles for doxycycline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxycycline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxycycline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxycycline

1. One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines

One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines Last updated: May (...) 21, 2019 Project Number: RC1121-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of one dose of doxycycline for the prevention of Lyme disease in patients with tick attachment? Are the evidence-based guidelines associated with the use of one dose of doxycycline for the prevention of Lyme disease in patients with tick attachment? Key Message Based primarily on a very-low quality randomized controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Doxycycline

Doxycycline Top results for doxycycline - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for doxycycline The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Full Text available with Trip Pro

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.We did a pragmatic, multicentre, parallel-group randomised controlled (...) trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3

2017 Lancet Controlled trial quality: predicted high

4. Azithromycin versus Doxycycline for Chlamydia. (Abstract)

Azithromycin versus Doxycycline for Chlamydia. 27144856 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1787 10.1056/NEJMc1600830 Geisler William M WM Perry Raymond C W RC Kerndt Peter R PR eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med (...) . 2016 May 5;374(18):1786 27144857 N Engl J Med. 2016 May 5;374(18):1786-7 27144858 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144856 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA3

2016 NEJM

5. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144857 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786 10.1056/NEJMc1600830 Schachter Julius J University of California, San Francisco, San Francisco, CA julius.schachter@ucsf.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 (...) Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144857 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA1

2016 NEJM

6. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144858 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786-7 10.1056/NEJMc1600830 Kreuter Alexander A Helios St. Elisabeth Hospital, Oberhausen, Germany alexander.kreuter@helios-kliniken.de. Wieland Ulrike U University of Cologne, Cologne, Germany. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 (...) Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144858 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA2

2016 NEJM

7. Acticlate Tablets (Doxycycline hyclate)

Acticlate Tablets (Doxycycline hyclate) Drug Approval Package: Brand Omtryg capsules NDA 204977 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Acticlate Tablets (Doxycycline hyclate) Company: Aqua Pharmaceuticals Application No.: 205931 Approval Date: 7/25/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package

8. Doxycycline

Doxycycline USE OF DOXYCYCLINE IN PREGNANCY 0344 892 0909 USE OF DOXYCYCLINE IN PREGNANCY (Date of issue: June 2012 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Doxycycline is a broad spectrum tetracycline antibiotic which is also used in the prophylaxis of malaria and as an adjunct to quinine (...) in the treatment of falciparum malaria. Exposure to doxycycline in early pregnancy has not been firmly associated with any specific malformations but its use in the second or third trimester can cause discolouration of the teeth. During pregnancy, travel to areas where malaria is endemic should be avoided wherever possible. If travel to such areas is unavoidable, chloroquine and proguanil are the preferred antimalarials to use during pregnancy. Doxycycline is best avoided for antimalarial prophylaxis during

2014 UK Teratology Information Service

9. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Full Text available with Trip Pro

Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans.To test whether doxycycline inhibits AAA progression in humans.Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345) SETTING: 14 Dutch hospitals.286 patients with small AAAs between October (...) 2008 and June 2011.Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months.The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery.Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups. Doxycycline treatment was associated with increased aneurysm growth (4.1 mm

2013 Annals of Internal Medicine Controlled trial quality: predicted high

10. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Full Text available with Trip Pro

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial (...) evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia. We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment.For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients (aged ≥15 years) from five centres in northeast

2013 Lancet Controlled trial quality: predicted high

11. Doxycycline monohydrate - Rosacea treatment

Doxycycline monohydrate - Rosacea treatment Common Drug Review CDEC Meeting — January 16, 2013; CDEC Reconsideration — March 20, 2013 Notice of CDEC Final Recommendation — March 27, 2013 Page 1 of 4 © 2013 CADTH FINAL CDEC RECOMMENDATION DOXYCYCLINE MONOHYDRATE (Apprilon – Galderma Canada Inc.) Indication: Inflammatory Rosacea Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that 40 mg doxycycline modified- release capsules not be listed. Reason for the Recommendation (...) : The Committee considered the comparative clinical benefit of 40 mg doxycycline modified- release (MR) capsules to be uncertain due to limitations in the design and analysis of the single randomized controlled trial (RCT) (ROSE-401) that compared 40 mg doxycycline MR capsules with 100 mg doxycycline immediate-release (IR) capsules. Background: Doxycycline monohydrate has a Health Canada indication for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline has

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

12. Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness

Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2012 CONTEXT AND POLICY ISSUES The potential use of anthrax as a biological terrorist attack has

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Doxycycline ineffective for osteoarthritis of the knee or hip

Doxycycline ineffective for osteoarthritis of the knee or hip PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Doxycycline ineffective for osteoarthritis of the knee or hip Clinical question How effective is doxycycline for osteoarthritis (OA) of the knee or hip? Bottom line Compared to placebo, there is minimal or no symptomatic benefit (pain reduction and improved physical function (...) ) with doxycycline treatment. The small benefit observed in joint space narrowing is of questionable clinical relevance and outweighed by safety issues. Doxycycline should therefore not be recommended for the treatment of osteoarthritis of the knee or hip. Caveat The trial was designed to detect differences in joint space narrowing rather than differences in clinical outcomes. No threshold for the level of knee pain was used for inclusion and the average level of knee pain was low at baseline, leaving little

2011 Cochrane PEARLS

14. Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein

Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein UTCAT856, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Subantimicrobial-Dose Doxycycline (SDD) Periodontal Therapy Reduces Serum Biomarkers Of Systemic Inflammation And Can Increase High-Density Lipoprotein Clinical Question In post-menopausal women with chronic (...) periodontitis does a systemic dose of Doxycycline in comparison to placebo increase high-density lipoprotein (HDL) levels? Clinical Bottom Line In post-menopausal women with chronic periodontitis Subantimicrobial-Dose Doxycycline Periodontal therapy reduces serum biomarkers of systemic inflammation and among women more than five years post-menopausal, the SDD regimen elevated their level of high-density lipoprotein (HDL) cholesterol. (See Comments on the CAT below) Best Evidence (you may view more info

2011 UTHSCSA Dental School CAT Library

15. Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine

Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-quality evidence that atovaquone-proguanil and doxycycline are better

2010 Evidence-Based Nursing

16. A randomized trial of doxycycline for Mansonella perstans infection. Full Text available with Trip Pro

A randomized trial of doxycycline for Mansonella perstans infection. Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies. The recent discovery of bacterial endosymbionts (e.g., wolbachia) in most filarial species, including M. perstans, provides new therapeutic options for reducing microfilaremia.In an open-label, randomized trial, we recruited (...) subjects with M. perstans microfilaremia, with or without concomitant W. bancrofti infection, from four villages in Mali and randomly assigned them to receive doxycycline, at a dose of 200 mg daily for 6 weeks (106 subjects), or no treatment (110). At 6 months, subjects who were coinfected with W. bancrofti underwent a second random assignment, to treatment with a single dose of albendazole (400 mg) and ivermectin (150 microg per kilogram of body weight) or no treatment. Subjects were monitored daily

2009 NEJM Controlled trial quality: uncertain

17. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial (Abstract)

Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial Use of intravenous penicillin and ceftriaxone to treat Lyme neuroborreliosis is well documented, although oral doxycycline could be a cost-effective alternative. We aimed to compare the efficacy of oral doxycycline with intravenous ceftriaxone for the treatment of Lyme neuroborreliosis.From April, 2004, to October, 2007, we recruited consecutive (...) adult patients from nine hospitals in southern Norway into a non-inferiority trial. Inclusion criteria were neurological symptoms suggestive of Lyme neuroborreliosis without other obvious causes, and presence of any of the following: a CSF white-cell count of more than five per mL; intrathecal production of specific Borrelia burgdorferi antibodies; or acrodermatitis chronicum atrophicans. Patients were randomly allocated to receive 200 mg oral doxycycline or 2 g intravenous ceftriaxone once per day

2008 EvidenceUpdates Controlled trial quality: predicted high

18. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. (Abstract)

Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. Tick-borne relapsing fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of postexposure treatment to prevent TBRF.In a double-blind, placebo-controlled trial, 93 healthy subjects with suspected tick exposure (52 with signs of tick bites and 41 close contacts--those without signs (...) but with a similar risk of contact with ticks) were randomly assigned to receive either doxycycline (Dexxon, in a dose of 200 mg the first day and then 100 mg per day for four days) or placebo after presumed exposure to TBRF. Cases of TBRF were defined by fever and a positive blood smear. Serologic analysis for cross-reactivity to Borrelia burgdorferi and polymerase chain reaction (PCR) for the borrelia glpQ gene were also performed.After randomization, 47 subjects (26 with signs of tick bites and 21 close

2006 NEJM Controlled trial quality: predicted high

19. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. (Abstract)

Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Wolbachia endosymbionts of filarial nematodes are vital for larval development and adult-worm fertility and viability. This essential dependency on the bacterium for survival of the parasites has provided a new approach to treat filariasis with antibiotics. We used this strategy to investigate the effects of doxycycline treatment on the major cause of lymphatic (...) filariasis, Wuchereria bancrofti.We undertook a double-blind, randomised, placebo-controlled field trial of doxycycline (200 mg per day) for 8 weeks in 72 individuals infected with W bancrofti from Kimang'a village, Pangani, Tanzania. Participants were randomly assigned by block randomisation to receive capsules of doxycycline (n=34) or placebo (n=38). We assessed treatment efficacy by monitoring microfilaraemia, antigenaemia, and ultrasound detection of adult worms. Follow-up assessments were done at 5

2005 Lancet Controlled trial quality: predicted high

20. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials

Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Lau C Y, Qureshi A K Authors' objectives To evaluate the efficacy and tolerance of azithromycin versus doxycycline for genital chlamydial infection. Searching (...) Studies published in English were retrieved from the following databases: MEDLINE and Pre-MEDLINE (from 1975 to August 2001), HealthSTAR (from 1975 to August 2001), EBM Reviews: Best Evidence (from September 1991 to January/February 2001), EBM Reviews: Cochrane Database of Systematic Reviews (second quarter of 2001), and EBM Reviews: DARE (second quarter of 2001). The medical subject headings 'CT' and 'doxycycline' or 'CT' and 'azithromycin' were used as search terms. Bibliographies of computer

2002 DARE.